ArticleBMC gastroenterology2025
The role of m6A regulators mRNA expression in peripheral blood mononuclear cells in chronic hepatitis B: a novel diagnostic and prognostic indicator.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundChronic hepatitis B (CHB) is a major health problem worldwide and is a major contributor to the progression of cirrhosis and hepatocellular carcinoma (HCC). Accurate monitoring of the immune response and liver inflammation in CHB patients is critical for effective disease management. N6-methyladenosine (m6A) plays a pivotal role in viral replication and immune modulation. However, the clinical significance of m6A regulators in the host immune system during CHB is still unclear. This study investigated the expression of key m6A regulators (METTL3, METTL14, IGF2BP3, and ALKBH5) in peripheral blood mononuclear cells (PBMCs) from CHB patients to explore their potential as noninvasive biomarkers for CHB diagnosis.
methodsA total of 119 participants were recruited, among which 101 were CHB patients and 18 were healthy controls. PBMCs were isolated, and the mRNA expression levels of four key m6A regulators were analysed via quantitative real-time PCR (qRT‒PCR). Spearman correlation analysis was used to investigate the relationships between m6A regulator expression and inflammatory markers. Univariate and multivariate logistic regression analyses were performed to identify independent risk factors for CHB.
resultsThe mRNA expression levels of METTL3 decreased in the LC, CHB (no-LC) (CHB without LC) and HC (healthy control) groups, and the differences were statistically significant (P < 0.05). METTL14 demonstrated a comparable expression pattern, although significant differences were evident only between the LC and HC groups (P < 0.05). ALKBH5 and IGF2BP3 levels were lower in LC patients than in CHB patients (non-LC patients) (P < 0.05). Moreover, METTL3 and METTL14 were negatively correlated with inflammation and cirrhosis markers, such as the neutrophil‒lymphocyte ratio (NLR) and the platelet‒lymphocyte ratio (PLR), but positively correlated with the lymphocyte‒monocyte ratio (LMR) (P < 0.05). Univariate analysis identified METTL3, PLR and AST as significant predictors of CHB. Multivariate logistic regression confirmed that reduced METTL3 expression, PLR and AST were independent risk factors for CHB progression (P < 0.05).
conclusionThese findings suggest that m6A regulators, particularly METTL3, are associated with CHB progression and immune response modulation. METTL3, in combination with other inflammatory markers, is a promising non-invasive biomarker for monitoring CHB disease activity, providing new insights into HBV-related disease progression and potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.